Literature DB >> 10825417

Power output of fast and slow skeletal muscles of mdx (dystrophic) and control mice after clenbuterol treatment.

G S Lynch1, R T Hinkle, J A Faulkner.   

Abstract

The mdx mouse is the most commonly used animal model for Duchenne muscular dystrophy. We tested the null hypothesis that 20 weeks of clenbuterol treatment ( approximately 2 mg kg-1 day-1) of mdx and control mice would have no effect on the absolute and specific force (Po, kN m-2) and absolute and normalised power output (W kg-1) of extensor digitorum longus (EDL) and soleus muscles. For mdx and control mice, clenbuterol treatment produced modest increases in the mass of the two muscles but did not increase absolute or specific force or normalised power output. For absolute power output, only the EDL muscles of mdx mice showed a difference following treatment, with the power output of treated mice being 118 % that of the untreated mice. The modest effects of clenbuterol treatment on the dynamic properties of skeletal muscle provide little support for any improvement in muscle function for the dystrophic condition.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10825417

Source DB:  PubMed          Journal:  Exp Physiol        ISSN: 0958-0670            Impact factor:   2.969


  13 in total

1.  Force and power output of fast and slow skeletal muscles from mdx mice 6-28 months old.

Authors:  G S Lynch; R T Hinkle; J S Chamberlain; S V Brooks; J A Faulkner
Journal:  J Physiol       Date:  2001-09-01       Impact factor: 5.182

2.  Systemic administration of beta2-adrenoceptor agonists, formoterol and salmeterol, elicit skeletal muscle hypertrophy in rats at micromolar doses.

Authors:  James G Ryall; Martin N Sillence; Gordon S Lynch
Journal:  Br J Pharmacol       Date:  2006-03       Impact factor: 8.739

3.  Adeno-associated virus-mediated microdystrophin expression protects young mdx muscle from contraction-induced injury.

Authors:  Mingju Liu; Yongping Yue; Scott Q Harper; Robert W Grange; Jeffrey S Chamberlain; Dongsheng Duan
Journal:  Mol Ther       Date:  2005-02       Impact factor: 11.454

4.  Functional rescue of dystrophin-deficient mdx mice by a chimeric peptide-PMO.

Authors:  Haifang Yin; Hong M Moulton; Corinne Betts; Thomas Merritt; Yiqi Seow; Shirin Ashraf; Qingsong Wang; Jordan Boutilier; Matthew Ja Wood
Journal:  Mol Ther       Date:  2010-08-10       Impact factor: 11.454

5.  Effects of botulinum toxin-induced paralysis on postnatal development of the supraspinatus muscle.

Authors:  Rosalina Das; Jason Rich; H Mike Kim; Audrey McAlinden; Stavros Thomopoulos
Journal:  J Orthop Res       Date:  2010-08-27       Impact factor: 3.494

6.  Sildenafil reduces respiratory muscle weakness and fibrosis in the mdx mouse model of Duchenne muscular dystrophy.

Authors:  Justin M Percival; Nicholas P Whitehead; Marvin E Adams; Candace M Adamo; Joseph A Beavo; Stanley C Froehner
Journal:  J Pathol       Date:  2012-07-18       Impact factor: 7.996

7.  Prevention of dystrophic pathology in severely affected dystrophin/utrophin-deficient mice by morpholino-oligomer-mediated exon-skipping.

Authors:  Aurélie Goyenvalle; Arran Babbs; Dave Powell; Ryszard Kole; Sue Fletcher; Steve D Wilton; Kay E Davies
Journal:  Mol Ther       Date:  2009-10-20       Impact factor: 11.454

8.  Second-generation compound for the modulation of utrophin in the therapy of DMD.

Authors:  Simon Guiraud; Sarah E Squire; Benjamin Edwards; Huijia Chen; David T Burns; Nandini Shah; Arran Babbs; Stephen G Davies; Graham M Wynne; Angela J Russell; David Elsey; Francis X Wilson; Jon M Tinsley; Kay E Davies
Journal:  Hum Mol Genet       Date:  2015-05-01       Impact factor: 6.150

9.  Pharmacological therapeutics targeting the secondary defects and downstream pathology of Duchenne muscular dystrophy.

Authors:  Janelle M Spinazzola; Louis M Kunkel
Journal:  Expert Opin Orphan Drugs       Date:  2016-10-18       Impact factor: 0.694

10.  Overexpression of the mitochondrial T3 receptor induces skeletal muscle atrophy during aging.

Authors:  François Casas; Laurence Pessemesse; Stéphanie Grandemange; Pascal Seyer; Olivier Baris; Naïg Gueguen; Christelle Ramonatxo; Florence Perrin; Gilles Fouret; Laurence Lepourry; Gérard Cabello; Chantal Wrutniak-Cabello
Journal:  PLoS One       Date:  2009-05-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.